Boobalan Pachaiyappan
Stock Analyst at Roth MKM
(0.07)
# 4,810
Out of 5,108 analysts
247
Total ratings
34.8%
Success rate
-14.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRDA Entrada Therapeutics | Reiterated: Buy | $11 → $10 | $4.55 | +119.78% | 23 | Nov 5, 2026 | |
| PMN ProMIS Neurosciences | Rated: Buy | $29 → $15 | $3.65 | +310.96% | 4 | Nov 2, 2026 | |
| PYPD PolyPid | Reiterated: Buy | $8 | $5.67 | +41.09% | 22 | Oct 29, 2026 | |
| RNA Atrium Therapeutics | Initiated Coverage: Buy | $15 | $8.32 | +80.29% | 1 | Oct 22, 2026 | |
| COYA Coya Therapeutics | Reiterated: Buy | $12 | $2.81 | +327.05% | 4 | Oct 15, 2026 | |
| CRVO CervoMed | Reiterated: Buy | $7 | $1.45 | +382.76% | 23 | Oct 13, 2026 | |
| NRSN NeuroSense Therapeutics | Downgraded: Hold | $60 → $3.5 | $1.40 | +150.90% | 7 | Oct 13, 2026 | |
| CAPR Capricor Therapeutics | Reiterated: Hold | $7 | $8.60 | -18.60% | 19 | Oct 6, 2026 | |
| SWX: NWRN Newron Pharmaceuticals S.p.A. | Rated: Buy | CHF 19.00 | CHF 8.75 | +117.14% | 1 | Oct 5, 2026 | |
| LBRX LB Pharmaceuticals | Downgraded: Hold | $37 → $35 | $38.09 | -8.11% | 6 | Oct 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $17 | $3.91 | +334.78% | 1 | Sep 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 | $1.45 | +313.79% | 1 | Sep 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $0.6689 | +946.49% | 3 | Sep 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 → $8 | $2.58 | +210.08% | 5 | Sep 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 → $29 | $7.32 | +296.17% | 6 | Sep 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $10 → $9 | $4.24 | +112.26% | 26 | Aug 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $1.71 | +1,654.39% | 17 | Aug 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $0.9604 | +732.99% | 29 | Aug 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $1 | $0.34 | +194.12% | 8 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $10.61 | n/a | 11 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.361 | n/a | 3 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.402 | n/a | 2 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $42.71 | n/a | 9 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $8.40 | n/a | 5 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $21.86 | n/a | 6 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $0.3 | $9.60 | n/a | 5 | Sep 19, 2023 |
Entrada Therapeutics
Nov 5, 2026
Reiterated: Buy
Price Target: $11 → $10
Current: $4.55
Upside: +119.78%
ProMIS Neurosciences
Nov 2, 2026
Rated: Buy
Price Target: $29 → $15
Current: $3.65
Upside: +310.96%
PolyPid
Oct 29, 2026
Reiterated: Buy
Price Target: $8
Current: $5.67
Upside: +41.09%
Atrium Therapeutics
Oct 22, 2026
Initiated Coverage: Buy
Price Target: $15
Current: $8.32
Upside: +80.29%
Coya Therapeutics
Oct 15, 2026
Reiterated: Buy
Price Target: $12
Current: $2.81
Upside: +327.05%
CervoMed
Oct 13, 2026
Reiterated: Buy
Price Target: $7
Current: $1.45
Upside: +382.76%
NeuroSense Therapeutics
Oct 13, 2026
Downgraded: Hold
Price Target: $60 → $3.5
Current: $1.40
Upside: +150.90%
Capricor Therapeutics
Oct 6, 2026
Reiterated: Hold
Price Target: $7
Current: $8.60
Upside: -18.60%
Newron Pharmaceuticals S.p.A.
Oct 5, 2026
Rated: Buy
Price Target: CHF 19.00
Current: CHF 8.75
Upside: +117.14%
LB Pharmaceuticals
Oct 5, 2026
Downgraded: Hold
Price Target: $37 → $35
Current: $38.09
Upside: -8.11%
Sep 19, 2026
Initiated Coverage: Buy
Price Target: $17
Current: $3.91
Upside: +334.78%
Sep 19, 2026
Initiated Coverage: Buy
Price Target: $6
Current: $1.45
Upside: +313.79%
Sep 4, 2026
Reiterated: Buy
Price Target: $7
Current: $0.6689
Upside: +946.49%
Sep 3, 2026
Reiterated: Buy
Price Target: $7 → $8
Current: $2.58
Upside: +210.08%
Sep 1, 2026
Reiterated: Buy
Price Target: $19 → $29
Current: $7.32
Upside: +296.17%
Aug 24, 2026
Rated: Buy
Price Target: $10 → $9
Current: $4.24
Upside: +112.26%
Aug 19, 2026
Reiterated: Buy
Price Target: $30
Current: $1.71
Upside: +1,654.39%
Aug 18, 2026
Reiterated: Buy
Price Target: $8
Current: $0.9604
Upside: +732.99%
Apr 1, 2026
Rated: Buy
Price Target: $30 → $1
Current: $0.34
Upside: +194.12%
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $10.61
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $0.361
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $0.402
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $42.71
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $8.40
Upside: n/a
Oct 24, 2023
Reiterated: Hold
Price Target: n/a
Current: $21.86
Upside: n/a
Sep 19, 2023
Reiterated: Hold
Price Target: $0.3
Current: $9.60
Upside: n/a